Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Al-Batran, S. -E. | - |
dc.contributor.author | Van Cutsem, E. | - |
dc.contributor.author | Oh, S. C. | - |
dc.contributor.author | Bodoky, G. | - |
dc.contributor.author | Shimada, Y. | - |
dc.contributor.author | Hironaka, S. | - |
dc.contributor.author | Sugimoto, N. | - |
dc.contributor.author | Lipatov, O. N. | - |
dc.contributor.author | Kim, T. -Y. | - |
dc.contributor.author | Cunningham, D. | - |
dc.contributor.author | Rougier, P. | - |
dc.contributor.author | Muro, K. | - |
dc.contributor.author | Liepa, A. M. | - |
dc.contributor.author | Chandrawansa, K. | - |
dc.contributor.author | Emig, M. | - |
dc.contributor.author | Ohtsu, A. | - |
dc.contributor.author | Wilke, H. | - |
dc.date.accessioned | 2021-09-04T01:11:06Z | - |
dc.date.available | 2021-09-04T01:11:06Z | - |
dc.date.created | 2021-06-17 | - |
dc.date.issued | 2016-04 | - |
dc.identifier.issn | 0923-7534 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/89113 | - |
dc.description.abstract | The phase III RAINBOW trial showed the addition of ramucirumab to paclitaxel yielded survival benefits for previously treated patients with advanced gastric or gastroesophageal junction adenocarcinoma. Now analyses reveal that ramucirumab also maintains patient-reported quality of life, lengthening the time to deterioration of patient symptoms and functions, and slowing performance status decline.The phase III RAINBOW trial demonstrated that the addition of ramucirumab to paclitaxel improved overall survival, progression-free survival, and tumor response rate in fluoropyrimidine-platinum previously treated patients with advanced gastric/gastroesophageal junction (GEJ) adenocarcinoma. Here, we present results from quality-of-life (QoL) and performance status (PS) analyses. Patients with Eastern Cooperative Oncology Group PS of 0/1 were randomized to receive ramucirumab (8 mg/kg i.v.) or placebo on days 1 and 15 of a 4-week cycle, with both arms receiving paclitaxel (80 mg/m(2)) on days 1, 8, and 15. Patient-reported outcomes were assessed with the QoL/health status questionnaires EORTC QLQ-C30 and EQ-5D at baseline and 6-week intervals. PS was assessed at baseline and day 1 of every cycle. Time to deterioration (TtD) in each QLQ-C30 scale was defined as randomization to first worsening of a parts per thousand yen10 points (on 100-point scale) and TtD in PS was defined as first worsening to a parts per thousand yen2. Hazard ratios (HRs) for treatment effect were estimated using stratified Cox proportional hazards models. Of the 665 patients randomized, 650 (98%) provided baseline QLQ-C30 and EQ-5D data, and 560 (84%) also provided data from a parts per thousand yen1 postbaseline time point. Baseline scores for both instruments were similar between arms. Of the 15 QLQ-C30 scales, 14 had HR < 1, indicating similar or longer TtD in QoL for ramucirumab + paclitaxel. Treatment with ramucirumab + paclitaxel was also associated with a delay in TtD in PS to a parts per thousand yen2 (HR = 0.798, P = 0.0941). Alternate definitions of PS deterioration yielded similar results: PS a parts per thousand yen 3 (HR = 0.656, P = 0.0508), deterioration by a parts per thousand yen1 PS level (HR = 0.802, P = 0.0444), and deterioration by a parts per thousand yen2 PS levels (HR = 0.608, P = 0.0063). EQ-5D scores were comparable between treatment arms, stable during treatment, and worsened at discontinuation. In patients with previously treated advanced gastric/GEJ adenocarcinoma, addition of ramucirumab to paclitaxel prolonged overall survival while maintaining patient QoL with delayed symptom worsening and functional status deterioration. NCT01170663. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | OXFORD UNIV PRESS | - |
dc.subject | SUPPORTIVE CARE | - |
dc.subject | CANCER | - |
dc.subject | CHEMOTHERAPY | - |
dc.subject | DOCETAXEL | - |
dc.subject | IMPACT | - |
dc.title | Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Oh, S. C. | - |
dc.identifier.doi | 10.1093/annonc/mdv625 | - |
dc.identifier.scopusid | 2-s2.0-84964688031 | - |
dc.identifier.wosid | 000374237700017 | - |
dc.identifier.bibliographicCitation | ANNALS OF ONCOLOGY, v.27, no.4, pp.673 - 679 | - |
dc.relation.isPartOf | ANNALS OF ONCOLOGY | - |
dc.citation.title | ANNALS OF ONCOLOGY | - |
dc.citation.volume | 27 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 673 | - |
dc.citation.endPage | 679 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | SUPPORTIVE CARE | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | DOCETAXEL | - |
dc.subject.keywordPlus | IMPACT | - |
dc.subject.keywordAuthor | quality of life | - |
dc.subject.keywordAuthor | gastric cancer | - |
dc.subject.keywordAuthor | GEJ cancer | - |
dc.subject.keywordAuthor | ramucirumab | - |
dc.subject.keywordAuthor | EORTC QLQ-C30 | - |
dc.subject.keywordAuthor | EQ-5D | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.